Quick Answer
BioNexus Gene Lab Corp reported Total Revenue of $9.51 million for fiscal year 2024.
BioNexus Gene Lab Corp — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Revenue | $9.51M -2.7% |
$9.77M -10.6% |
$10.93M -18.2% |
$13.36M +17.3% |
$11.39M +8872.0% |
$127.0K -40.2% |
| Net Income | -$1.60M +39.2% |
-$2.63M -638.6% |
-$356.0K -147.4% |
$751.6K -31.3% |
$1.09M +543.9% |
-$246.5K -1031.7% |
| Diluted EPS | -$0.09 +45.8% |
-$0.17 | — | — | — | — |
| Total Assets | $10.43M -8.5% |
$11.40M +30.4% |
$8.74M -8.7% |
$9.57M -5.3% |
$10.12M +721.6% |
$1.23M -25.5% |
| Cash and Equivalents | — | — | — | $2.12M -23.8% |
$2.79M +224.5% |
$859.1K -31.8% |
| Stockholders Equity | $8.32M -13.8% |
$9.66M +44.9% |
$6.67M -7.2% |
$7.18M +7.8% |
$6.66M +493.6% |
$1.12M -26.3% |
| R&D Expense | $47.5K -13.6% |
$55.0K | — | — | — | — |
| Operating Income | -$1.57M +39.3% |
-$2.59M -790.7% |
-$291.2K -127.6% |
$1.06M -17.1% |
$1.27M +562.0% |
-$275.7K -560.3% |
| Gross Profit | $1.29M -3.0% |
$1.33M +5.6% |
$1.26M -44.5% |
$2.27M +31.8% |
$1.72M +2977.3% |
$55.9K +94.3% |
| Shares Outstanding | 17.97M +1.7% |
17.67M +22.0% |
14.48M -91.5% |
171.22M +0.0% |
171.22M +66.7% |
102.73M +37.7% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $2.54M | -3.3% | +12.5% |
| Net Income | September 30, 2025 | -$709.0K | +47.3% | -15.1% |
| Diluted EPS | September 30, 2025 | -$0.40 | +47.3% | -15.2% |
| Total Assets | September 30, 2025 | $7.62M | -30.7% | -19.1% |
| Cash and Equivalents | March 31, 2022 | $1.84M | -25.5% | -13.2% |
| Stockholders Equity | September 30, 2025 | $6.82M | -27.4% | -9.4% |
| R&D Expense | September 30, 2025 | $14.9K | +42.5% | +18.5% |
| Operating Income | September 30, 2025 | -$702.5K | +47.5% | -14.9% |
| Gross Profit | September 30, 2025 | $377.7K | +15.7% | +2.6% |
| Shares Outstanding | September 30, 2025 | 1.80M | -90.0% | +0.0% |
- BioNexus Gene Lab Corp reported Total Revenue of $9.51 million for fiscal year 2024.
- BioNexus Gene Lab Corp showed a decrease of -2.7% in Total Revenue compared to the prior fiscal year.
- BioNexus Gene Lab Corp reported Net Income of -$1.60 million for fiscal year 2024.
- BioNexus Gene Lab Corp showed an increase of +39.2% in Net Income compared to the prior fiscal year.
- BioNexus Gene Lab Corp reported Diluted EPS of $0.09 per share (loss) for fiscal year 2024.
- BioNexus Gene Lab Corp showed an increase of +45.8% in Diluted EPS compared to the prior fiscal year.
- BioNexus Gene Lab Corp reported Total Assets of $10.43 million for fiscal year 2024.
- BioNexus Gene Lab Corp showed a decrease of -8.5% in Total Assets compared to the prior fiscal year.
- BioNexus Gene Lab Corp reported Cash and Equivalents of $2.12 million for fiscal year 2021.
- BioNexus Gene Lab Corp showed a decrease of -23.8% in Cash and Equivalents compared to the prior fiscal year.
- BioNexus Gene Lab Corp reported Stockholders Equity of $8.32 million for fiscal year 2024.
- BioNexus Gene Lab Corp showed a decrease of -13.8% in Stockholders Equity compared to the prior fiscal year.
- BioNexus Gene Lab Corp reported R&D Expense of $47.5 thousand for fiscal year 2024.
- BioNexus Gene Lab Corp showed a decrease of -13.6% in R&D Expense compared to the prior fiscal year.
- BioNexus Gene Lab Corp reported Operating Income of -$1.57 million for fiscal year 2024.
- BioNexus Gene Lab Corp showed an increase of +39.3% in Operating Income compared to the prior fiscal year.
- BioNexus Gene Lab Corp reported Gross Profit of $1.29 million for fiscal year 2024.
- BioNexus Gene Lab Corp showed a decrease of -3.0% in Gross Profit compared to the prior fiscal year.
- BioNexus Gene Lab Corp reported Shares Outstanding of 17.97 million shares for fiscal year 2024.
- BioNexus Gene Lab Corp showed an increase of +1.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: